drugset / Trial / NCT03186456

The Safety and Efficacy of Human Umbilical Cord Mesenchymal Stem Cells (19#iSCLife®-ACI) in the Treatment of Acute Cerebral Infarction

NCT03186456

Phase 1 Suspended 40 enrolled Sclnow Biotechnology Co., Ltd.
RandomizedParallel-groupDouble-blindTreatment

Summary

The purposes of the study is to determine the safety and efficacy of treating acute ischemic stroke patients with human umbilical cord mesenchymal stem cells (hUC-MSC).

Timeline

Start
2026-12-31
Primary completion
2027-06-30
Completion
2027-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Allogeneic umbilical cord mesenchymal stem cells Cell therapy 500000 cells/kg Intravenous
Subject Allogeneic umbilical cord mesenchymal stem cells Cell therapy 1e+06 cells/kg Intravenous
Background Aspirin Small molecule 100 mg

Indications